1. A pharmaceutical composition comprising morphine aminophenazone analgin acetyl-salicylic acid indomethacin ibuprofen diclophenac or codeine as an active analgetic ingredient and theobromine as a compound of xanthine structure where the ratio of the analgesic active ingredient and theobromine is (1-20): 1 advantageously 10: 1. 2. The pharmaceutical composition according to claim 1 comprising analgin S (+) ibuprophen or diclofenac as the analgesic active ingredients. 3. The pharmaceutical compo...

The subject of the invention is a pharmaceutical composition comprising as active ingredient an analgesic compound and a compound of xanthine structure where the ratio of the analgesic and the xanthine derivatives is (1-20):1 advantageously 10:1. As analgesic compound preferably morphine aminophenazone analgin acetyl-salicylic acid indomethacin ibuprofen diclophenac codeine more preferably analgin S(+)ibuprofen diclophenac as a compound of xanthine structure 3-methylxanthine theobromine or CH-13...

Novel substrates which are amino acid 4-amino phenazones for detecting enzymes particularly L-gamma-glutamyltransferase are described. The amino acid gamma-glutamyl-4-aminophenazone reacts with the enzyme to produce 4-aminophenazone which is an amino dye intermediate. The amino dye intermediate is coupled with a second dye intermediate to form a chromogen. The 4-aminophenazone is particularly reacted with a phenolic naphtholic or aniline compound particularly the phenolic compound 2-hydroxy-35-d...

A water-dispersible veterinary preparation comprises (a) up to 50% by weight of a therapeutically active substance (b) from 2 to 70% by weight of a polyethyleneglycol which is solid at room temperature and (c) from 10 to 70% by weight of an amphiphilic agent which is solid at room temperature the preparation being in the form of particles the major portion of which have a diameter within the range of 50-200m . The polyethyleneglycol may have an average molecular weight of 2000-10000. The amphi...

A water-dispersible veterinary preparation comprises (a) up to 50% by weight of a therapeutically active substance (b) from 2 to 70% by weight of a polyethyleneglycol which is solid at room temperature and (c) from 10 to 70% by weight of an amphiphilic agent which is solid at room temperature the preparation being in the form of particles the major portion of which have a diameter within the range of 50-200m . The polyethyleneglycol may have an average molecular weight of 2000-10000. The amphi...